Merck Januvia (sitagliptin by Year

Name: Merck Januvia (sitagliptin by Year (MRK)
Creator: Merck

Januvia (sitagliptin — DPP-4 inhibitor) — U.S. reported growth YoY (%) (%)

Quarterly Annual

Merck Januvia (sitagliptin: 113.0% in FY2025, up 172.0 pts from a year earlier.

Latest, FY2025

113.0%

Period ended Dec 31, 2025

Change on a year earlier

+172.0 pts

-59.0% in FY2024

History

7 years

Since FY2017

Sources

Documents cited below

Where the FY2025 figure comes from

“|| Januvia | 1,604 | 1,334 | 20 | 999 | 469 | 113 | 605 | 865 | -30”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Januvia (sitagliptin — DPP-4 inhibitor) — U.S. reported growth YoY (%) (%)	Year on year	Source
FY2025	Dec 31, 2025	113.0%	+172.0 pts	Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024	Dec 31, 2024	-59.0%	-51.0 pts	Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2023	Dec 31, 2023	-8.0%	–	Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021	Dec 31, 2021	-4.0%	–	Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019	Dec 31, 2019	-12.0%	-3.0 pts	Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018	Dec 31, 2018	-9.0%	-3.0 pts	Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017	Dec 31, 2017	-6.0%	–	Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Januvia (sitagliptin (%), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-januvia-us-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.